Mersana Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Bain Capital Life Sciences reports 0% ownership in Mersana Therapeutics following its acquisition by Day One Biopharmaceuticals for $25.00 cash plus CVR per share.
Bain Capital Life Sciences entities have agreed to tender their 6.9% stake in Mersana Therapeutics as part of a tender offer by Day One Biopharmaceuticals.